Somru BioScience Inc. develops breakthrough antibody technology for research, diagnostic and therapeutic applications. The company uses antibodies to generate reagents that accelerate biosimilar research and development.
The company has stepped up during the COVID-19 pandemic to be part of the solution.
They are working on multiple projects to develop research solutions to combat the outbreak.
“We are honoured to be a part of Premier King’s Council on Recovery and Growth,” says Mohammed Moin, CEO of Somru BioScience Inc. in Charlottetown.
“The work of this group will be critical in establishing a plan for recovery and growth potential for our province over the next one, two, five and 10 years. Somru will play a vital role to accelerate the economic growth in post-corona world.
“We export to 27 countries now, and are looking to double our workforce in 2022,” Moin says.
“We are looking to grow further in Europe and Asia with a strong focus on improvements to our systems and processes such as automated kit assembly, electronic assay worksheets, and data analysis tools.”
For more information, visit www.somrubioscience.com.
Bioscience companies and their employees are flexing their research, development, and manufacturing muscle to help in the fight against COVID-19.
PEI BioAlliance members and other specialized manufacturers are not only maintaining their regular operations, but are also part of Canada’s response to the crisis.
PEI companies and research teams are developing protective equipment and medical devices, products to strengthen human resistance to diseases, technologies to test if someone is or has been infected by COVID-19, and technologies to give specialists an online view for remote diagnoses. Here are eleven examples below.
Somru BioScience is drawing on its antibody platform technology to assist in developing therapeutic and diagnostic solutions for COVID-19 and other infectious diseases. Their experience in immunoassay development will enable them to provide diagnostic and research solutions for future infectious disease outbreaks.
Somru’s plans include shortening the development time of diagnostic kits for future infectious diseases by 50 percent. For full details, click here